SCHEMBL4059650

SCHEMBL4059650

Fc1ccccc1-c1ccc2nc(-c3ccc4ncccc4c3)oc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VSIR Q9H7M9 1/20 0.54
UTRN P46939 3/20 0.51
NPC1 O15118 5/20 0.48
RAB9A P51151 4/20 0.48
POLB P06746 1/20 0.48
KDM4E B2RXH2 5/20 0.47
BACE1 P56817 1/20 0.47
GPR119 Q8TDV5 1/20 0.45
AKR1C3 P42330 1/20 0.45
AKR1C2 P52895 1/20 0.45
ALDH1A1 P00352 3/20 0.44
HPGD P15428 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
HSD17B10 Q99714 2/20 0.44
HCRTR1 O43613 1/20 0.44
USP2 O75604 1/20 0.44
MAPT P10636 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
CASP3 P42574 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27998035 0.85 NPC1 (0.65) NPC1RAB9APOLBKDM4EBACE1
SCHEMBL4054476 0.83 VSIR (0.61) VSIRNPC1RAB9APOLBKDM4E
SCHEMBL15844951 0.82 NPC1 (0.63) UTRNNPC1RAB9APOLBKDM4E
SCHEMBL4054275 0.81 VSIR (0.63) VSIRUTRNNPC1RAB9AKDM4E
SCHEMBL4062955 0.81 VSIR (0.56) VSIRNPC1RAB9AKDM4EBACE1
SCHEMBL4054584 0.79 NPC1 (0.61) VSIRNPC1RAB9AKDM4EBACE1
SCHEMBL4058059 0.79 VSIR (0.61) VSIRNPC1RAB9APOLBKDM4E
SCHEMBL18308642 0.79 GRM4 (0.46) VSIRUTRNNPC1RAB9APOLB
SCHEMBL4056655 0.78 UTRN (0.56) UTRNNPC1RAB9APOLBKDM4E
SCHEMBL4060257 0.78 VSIR (0.51) VSIRNPC1RAB9AKDM4EBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B VSIR 4618/4885UTRN 4874/4885NPC1 4740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.